BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Yahoo Finance ·
BioNTech ( BNTX -0.90% ) and Moderna ( MRNA -1.29% ) burst onto the scene during the pandemic. Both developed and marketed some of the most successful mRNA-based coronavirus vaccines and were handsomely rewarded for it. However, their financial results have worsened as the pandemic has waned, and they have lagged broader equities over the past five years. Now for the good news: BioNTech and Moderna may have bright futures as they advance their vaccine candidates. But which one will deliver stronger returns? BioNTech boasts a deep pipeline of candidates. One of the most promising products it is working on is called pumitamig. The biotech is developing it in collaboration with Bristol Myers Squibb ( BMY +0.64% ) . What's so special about pumitamig? It is one of those newer cancer drugs dubbed potential "Keytruda Killers," or medicines that could challenge Merck 's ( MRK +0.46% ) Keytruda, the world's best-selling cancer drug. BioNTech is testing pumitamig across several potential indications, including lung cancer, the leading cause of cancer death. We should see more clinical trial data from pumitamig within the next 18 months. Positive results could send BioNTech's shares soaring.
DYAX Investor Sentiment
Bullish (Long) 50% · Bearish (Short) 50%
348 participants
Related News
- Nvidia’s $12.93 Billion Hugging Face Deal Expands Jensen Huang's AI Platform Beyond Chips
- S&P 500, Dow End Best Day In A Month On Calmer Yields As Rate Hike Bets Wane — SPCX, VSXY, NVDA, TSLA In Focus
- Micron (MU) to double HBM production capacity, narrowing gap with SK Hynix (000660 KS) and Samsung Electronics (005930 KS)
- Alcatraz AI Names Bobby Louissaint Head of Business Development
- Former Meta Superintelligence Labs Agentic AI Lead Joins Project 777, Strengthening Technical Leadership Alongside Former U.S. Space Force CTO Preston Dunlap
- AI Infrastructure Demand Remains Red-Hot: HPE, AVGO, DELL Deliver
